Aurobindo Pharma Limited has informed the Exchange about classification of Unit-VII of Aurobindo Pharma Limited, as Voluntary Action Indicated (VAI)
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Midcap 150 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aurobindo Pharma's Unit-VII, an oral solid dosage manufacturing facility in Jedcherla, Telangana, has received an Establishment Inspection Report (EIR) from the US FDA classifying it as Voluntary Action Indicated (VAI). The FDA had inspected the facility from January 28 to February 10, 2026, and issued a Form 483 with 9 observations at the end of the inspection. The FDA has now concluded that the inspection is closed. VAI is a relatively benign classification where the FDA recommends voluntary improvements but does not pursue regulatory action.
The VAI classification and closed inspection status removes regulatory uncertainty around this facility. While the 9 Form 483 observations indicate quality concerns, the lack of enforcement action is positive for the company's US market access. Shareholders should monitor whether the company implements recommended corrective actions.